The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Wed., Dec. 11, 7:28 AM

Slide #12. Kodiak Sciences Inc. Secondary Offering

Company: Kodiak Sciences Inc. (NASDAQ:KOD)
Date announced: 12/2/2019
Shares Offered: 6,000,000
Date of Pricing: 12/3/2019
Price Per Share: $46.00
Secondary Offering Details: Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it has commenced an underwritten public offering of $250,000,000 of shares of its common stock. In connection with the proposed offering, Kodiak Sciences expects to grant the underwriters a 30-day option to purchase up to an additional $37,500,000 of shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the proposed offering will be sold by Kodiak Sciences. The proposed offering is subject to market and other conditions, and there can be no assurances as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering. -updated 12/3- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a price to the public of $46.00 per share. The aggregate gross proceeds from the offering are expected to be approximately $276.0 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Kodiak Sciences. The offering is expected to close on or about December 6, 2019, subject to customary closing conditions. In connection with the offering, Kodiak Sciences has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock at the public offering price, less underwriting discounts and commissions.

Kodiak Sciences is a clinical-stage biopharmaceutical company focusing on therapeutics to treat chronic, high-prevalence retinal diseases. Co.'s main product candidate is KSI-301, a biologic therapy built with Co.'s antibody biopolymer conjugate platform, which is designed to maintain drug levels in ocular tissues. KSI-301, is an anti-vascular endothelial growth factor therapy in wet age-related macular degeneration, diabetic retinopathy, including diabetic macular edema, and other retinal vascular diseases. Co. is also developing additional product candidates beyond KSI-301, including KSI-501, its bispecific anti-IL-6/VEGF bioconjugate for diabetic eye disease and uveitis.

KOD SEC Filing Email Alerts Service

Open the KOD Page at The Online Investor »

Company Name:  Kodiak Sciences Inc
Website:  www.kodiak.com
Sector:  Biotechnology
Number of ETFs Holding KOD:  14
Total Market Value Held by ETFs:  $113.62M
Total Market Capitalization:  $2.39B
% of Market Cap. Held by ETFs:  4.76%
 

Open the KOD Page at The Online Investor (in a new window) »

December 11, 2019    7:28 AM Eastern
Quotes delayed 20 minutes



Strong Buy (3.50 out of 4)
62nd percentile
(ranked higher than approx. 62% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2019, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.